InflaRx N.V. (NASDAQ:IFRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX) have earned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $7.00.

A number of research analysts recently weighed in on IFRX shares. Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $7.00 to $9.00 in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. Oppenheimer began coverage on shares of InflaRx in a report on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective for the company. Guggenheim reiterated a “buy” rating and issued a $14.00 price target on shares of InflaRx in a research note on Tuesday, April 21st. Finally, HC Wainwright lifted their price target on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 11th.

InflaRx Stock Performance

Shares of IFRX stock opened at $2.61 on Friday. The stock has a market capitalization of $188.68 million, a P/E ratio of -3.68 and a beta of 2.42. The company has a 50 day moving average price of $1.53 and a 200 day moving average price of $1.22. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $2.95.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. On average, research analysts forecast that InflaRx will post -0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC purchased a new position in InflaRx in the third quarter worth approximately $214,000. Susquehanna International Group LLP purchased a new position in InflaRx in the third quarter worth approximately $190,000. XTX Topco Ltd purchased a new position in InflaRx in the fourth quarter worth approximately $135,000. Quadrature Capital Ltd purchased a new position in InflaRx in the fourth quarter worth approximately $104,000. Finally, Insigneo Advisory Services LLC purchased a new position in InflaRx in the fourth quarter worth approximately $61,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.